Vasculitis & polymyalgia rheumatica
Cost effectiveness of avacopan for ANCA-associated vasculitis in China
Main finding · QALYs, LYs, total costs and ICERResult — go to the resultICER $6,146 per QALYAuthors' conclusion
Avacopan-based regimens are cost-effective versus GC-based therapy for GPA/MPA in China
Study context
- Population
- Adults with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in China; baseline characteristics from the ADVOCATE trial
- Comparison
- Avacopan plus CYC or rituximab (RTX) with reduced-dose glucocorticoid (GCs) vs CYC/RTX plus standard GCs
- Outcome
- ICER (cost per QALY gained) at a WTP threshold of one time China's 2024 GDP per capita per QALY
Methodological detailsnine-state Markov model, Chinese healthcare system perspective, one-way, probabilistic and scenario sensitivity analyses, threshold price analysis, Treatment shares followed trial allocation (35.2% CYC; 64.8% RTX)
- Nine-state Markov model
- Chinese healthcare system perspective
- One-way, probabilistic and scenario sensitivity analyses
- Threshold price analysis
- Treatment shares followed trial allocation (35.2% CYC; 64.8% RTX)
Main finding
Quality-adjusted life years (QALYs), life-years (LYs), total costs and ICER
ICER
$6,146 per QALY
By group
As reported in the abstract
Further findings
Robustness in sensitivity and scenario analyses
- Results were robust in sensitivity and scenario analyses
Maximum cost-effective avacopan price at willingness-to-pay (WTPs) of 1.0-1.5 times GDP per capita
- Maximum cost-effective price per 10 mg
- $11.12-$12.70
Original publication
Cost effectiveness of avacopan for ANCA-associated vasculitis in China. Clin Exp Rheumatol. Published 13 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →